Department of Neurology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Clinic of Neurology, Ministry of Health Goztepe Training and Research Hospital, Istanbul, Turkey.
Int J Neurosci. 2021 Dec;131(12):1181-1189. doi: 10.1080/00207454.2020.1784165. Epub 2020 Jun 25.
To determine the serum expression levels of seven candidate microRNAs (miRNA); miR-19a, miR-19b, miR-29a, miR-29c, miR-181, miR-195 and miR-221 in Turkish patients with Parkinson's disease (PD) and explored their potential role in the diagnosis of PD. We further described the relationship between these miRNAs with the clinical findings and treatment of PD.
The study included 51 PD patients and 20 healthy controls. The clinical severity of disease was assessed using the Hoehn Yahr staging scale and the Unified Parkinson's Disease Rating Scale (UPDRS). Venous blood samples were taken after fasting for 12 h, then centrifuged. Obtained serum samples were stored until analysis of miRNA. In the laboratory, expression levels of these miRNAs were analyzed using a real-time PCR instrument. Receiver-operating characteristic analysis and area-under the-curve (AUC) was used to evaluate these miRNA levels as potential diagnostic biomarkers for PD.
miR-29c expression levels were increased significantly for PD patients compared to healthy controls. There were no significant differences in levels of other miRNAs between PD patients and controls. The AUC of miR-29c was 0.689. The sensitivity and specificity of this diagnostic test was 54.9% and 80.0%, respectively. miR-195 level was found to have a significant positive correlation only with age. Significant negative correlation was found between miR-29a level and UPDRS total score. miR-19b was found higher in ropinirole drug used group than that of pramipexole group.
This study suggests that serum miR-29c expression level might be potential biomarker in the diagnosis of Turkish Parkinson patients.
确定七种候选 microRNA（miRNA）；miR-19a、miR-19b、miR-29a、miR-29c、miR-181、miR-195 和 miR-221 在土耳其帕金森病（PD）患者中的血清表达水平，并探讨其在 PD 诊断中的潜在作用。我们进一步描述了这些 miRNA 与 PD 临床发现和治疗之间的关系。
该研究纳入了 51 名 PD 患者和 20 名健康对照者。采用 Hoehn Yahr 分期量表和统一帕金森病评定量表（UPDRS）评估疾病的临床严重程度。空腹 12 小时后抽取静脉血，然后离心。获得的血清样本在分析 miRNA 之前储存。在实验室中，使用实时 PCR 仪器分析这些 miRNA 的表达水平。采用接受者操作特征分析和曲线下面积（AUC）评估这些 miRNA 水平作为 PD 潜在诊断生物标志物的能力。
与健康对照组相比，PD 患者的 miR-29c 表达水平显著升高。PD 患者和对照组之间其他 miRNA 水平没有显著差异。miR-29c 的 AUC 为 0.689。该诊断试验的灵敏度和特异性分别为 54.9%和 80.0%。miR-195 水平仅与年龄呈显著正相关。miR-29a 水平与 UPDRS 总分呈显著负相关。发现 miR-19b 在罗匹尼罗药物使用组中的表达高于普拉克索组。
本研究表明，血清 miR-29c 表达水平可能是土耳其帕金森病患者潜在的诊断生物标志物。
